Maharashtra Deputy Chief Minister Ajit Pawar on Friday said over 300 cases of Mucormycosis, a fungal infection prevalent among people who have recovered from COVID-19, have been reported in Pune district and the supply of drugs needed for treatment is a cause for concern.
Speaking to reporters after reviewing the COVID-19 situation in Pune, Pawar, who is also the guardian minister of the district said the Centre has been apprised about the matter.
"There are over 300 cases of Mucormycosis or black fungus in Pune, including patients from other districts. However, there is a shortage of the anti-fungal drug Amphotericin B. As each patient requires six injections per day, we need 1,800 vials per day. Unfortunately, the supply isn't in keeping with the demand," the deputy chief minister said.
The state government had approached pharma companies, but it was in turn informed that the Centre has taken control of the drugs, he alleged.
"During the Prime Minister's interaction with district collectors of the states, the state government sought the drug and also apprised him about the shortage. Hope the situation changes and the drug supply is as per the demand," Pawar said.
Meanwhile, there has been a drop in the daily tally of COVID-19 cases in the district and the number of patients getting discharged is increasing, he said, adding that the rate of infection in the rural areas is still a cause for concern.
When asked about the supply of vaccines, Pawar said the state government is following up with the Centre for the vaccines.
"The Brihanmumbai Municipal Corporation (BMC) has issued a global tender. During our consultation with Serum Institute of India (SII) and Bharat Biotech, they told us that they will ramp up the production in the near future," he said.
Speaking about the state's preparedness to tackle the third wave of the pandemic, Pawar said a decision has been taken to increase the production of oxygen by 3,000 metric tonnes in the state and an incentive will be offered to industries to set up oxygen plants in remote areas.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)